These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27496180)

  • 1. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial.
    Pyle M; Norrie J; Schwannauer M; Kingdon D; Gumley A; Turkington D; Byrne R; Syrett S; MacLennan G; Dudley R; McLeod HJ; Griffiths H; Bowe S; Barnes TR; French P; Hutton P; Davies L; Morrison AP
    BMC Psychiatry; 2016 Aug; 16():280. PubMed ID: 27496180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT.
    Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe S; French P; Hutton P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TR; Davies L; Shields G; Buck D; Tully S; Kingdon D
    Health Technol Assess; 2019 Feb; 23(7):1-144. PubMed ID: 30806619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial.
    Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe SE; French P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TRE; Davies L; Kingdon D;
    Lancet Psychiatry; 2018 Aug; 5(8):633-643. PubMed ID: 30001930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.
    Rossell SL; Francis PS; Galletly C; Harris A; Siskind D; Berk M; Bozaoglu K; Dark F; Dean O; Liu D; Meyer D; Neill E; Phillipou A; Sarris J; Castle DJ
    BMC Psychiatry; 2016 Sep; 16(1):320. PubMed ID: 27629871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
    Cipriani A; Boso M; Barbui C
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006324. PubMed ID: 19588385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
    Nosè M; Accordini S; Artioli P; Barale F; Barbui C; Beneduce R; Berardi D; Bertolazzi G; Biancosino B; Bisogno A; Bivi R; Bogetto F; Boso M; Bozzani A; Bucolo P; Casale M; Cascone L; Ciammella L; Cicolini A; Cipresso G; Cipriani A; Colombo P; Dal Santo B; De Francesco M; Di Lorenzo G; Di Munzio W; Ducci G; Erlicher A; Esposito E; Ferrannini L; Ferrato F; Ferro A; Fragomeno N; Parise VF; Frova M; Gardellin F; Garzotto N; Giambartolomei A; Giupponi G; Grassi L; Grazian N; Grecu L; Guerrini G; Laddomada F; Lazzarin E; Lintas C; Malchiodi F; Malvini L; Marchiaro L; Marsilio A; Mauri MC; Mautone A; Menchetti M; Migliorini G; Mollica M; Moretti D; Mulè S; Nicholau S; Nosè F; Occhionero G; Pacilli AM; Pecchioli S; Percudani M; Piantato E; Piazza C; Pontarollo F; Pycha R; Quartesan R; Rillosi L; Risso F; Rizzo R; Rocca P; Roma S; Rossattini M; Rossi G; Rossi G; Sala A; Santilli C; Saraò G; Sarnicola A; Sartore F; Scarone S; Sciarma T; Siracusano A; Strizzolo S; Tansella M; Targa G; Tasser A; Tomasi R; Travaglini R; Veronese A; Ziero S
    Trials; 2009 May; 10():31. PubMed ID: 19445659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings.
    Casetta C; Santosh P; Bayley R; Bisson J; Byford S; Dixon C; Drake RJ; Elvins R; Emsley R; Fung N; Hayes D; Howes O; James A; James K; Jones R; Killaspy H; Lennox B; Marchant L; McGuire P; Oloyede E; Rogdaki M; Upthegrove R; Walters J; Egerton A; MacCabe JH
    BMC Psychiatry; 2024 Feb; 24(1):122. PubMed ID: 38355533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive-behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT.
    Goldstein LH; Robinson EJ; Pilecka I; Perdue I; Mosweu I; Read J; Jordan H; Wilkinson M; Rawlings G; Feehan SJ; Callaghan H; Day E; Purnell J; Baldellou Lopez M; Brockington A; Burness C; Poole NA; Eastwood C; Moore M; Mellers JD; Stone J; Carson A; Medford N; Reuber M; McCrone P; Murray J; Richardson MP; Landau S; Chalder T
    Health Technol Assess; 2021 Jun; 25(43):1-144. PubMed ID: 34196269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.
    Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D
    Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS).
    Pyle M; Broome MR; Joyce E; MacLennan G; Norrie J; Freeman D; Fowler D; Haddad PM; Shiers D; Hollis C; Smith J; Liew A; Byrne RE; French P; Peters S; Hudson J; Davies L; Emsley R; Yung A; Birchwood M; Longden E; Morrison AP
    Trials; 2019 Jul; 20(1):395. PubMed ID: 31272477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study.
    Qurashi I; Chu S; Husain N; Drake RJ; Chaudhry I; Deakin JF
    Trials; 2016 Nov; 17(1):553. PubMed ID: 27871302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
    Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
    Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.